Shares of Arcellx, Inc. (NASDAQ:ACLX – Get Free Report) have earned a consensus rating of “Buy” from the twelve research firms that are presently covering the firm, MarketBeat reports. Twelve investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have covered the stock in the […]
Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research note issued on Thursday, Benzinga reports. They presently have a $81.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 37.10% from the stock’s […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of current […]
Gilead Sciences (NASDAQ:GILD – Get Free Report) and Beam Therapeutics (NASDAQ:BEAM – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Earnings & Valuation This table compares Gilead Sciences […]
Scotiabank reissued their outperform rating on shares of Arcellx (NASDAQ:ACLX – Free Report) in a report published on Thursday morning, Stock Target Advisor reports. Scotiabank currently has a $82.00 price objective on the stock. ACLX has been the topic of a number of other research reports. Barclays increased their target price on Arcellx from $62.00 […]